The estimated Net Worth of James Brian Windsor is at least $15.5 Mille dollars as of 5 March 2024. Dr Windsor owns over 2,000 units of Tff Pharmaceuticals Inc stock worth over $15,455 and over the last 5 years he sold TFFP stock worth over $0.
Dr has made over 5 trades of the Tff Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 2,000 units of TFFP stock worth $4,340 on 5 March 2024.
The largest trade he's ever made was exercising 25,000 units of Tff Pharmaceuticals Inc stock on 7 December 2020 worth over $62,500. On average, Dr trades about 5,329 units every 228 days since 2019. As of 5 March 2024 he still owns at least 7,122 units of Tff Pharmaceuticals Inc stock.
You can see the complete history of Dr Windsor stock trades at the bottom of the page.
Dr. James Brian Windsor is the Chief Science Officer & Director at Tff Pharmaceuticals Inc.
Dr Windsor is 54, he's been the Chief Science Officer & Director of Tff Pharmaceuticals Inc since . There are 2 older and 2 younger executives at Tff Pharmaceuticals Inc. The oldest executive at Tff Pharmaceuticals Inc is Glenn R. Mattes, 66, who is the Pres, CEO & Director.
James's mailing address filed with the SEC is C/O AILERON THERAPEUTICS, INC., 738 MAIN STREET #398, WALTHAM, MA, 02451.
Over the last 5 years, insiders at Tff Pharmaceuticals Inc have traded over $27,239,579 worth of Tff Pharmaceuticals Inc stock and bought 1,894,491 units worth $5,305,961 . The most active insiders traders include Therapeutics, Inc. Lung, Aaron G.L. Fletcher e Harlan F Weisman. On average, Tff Pharmaceuticals Inc executives and independent directors trade stock every 25 days with the average trade being worth of $174,967. The most recent stock trade was executed by Harlan F Weisman on 15 August 2023, trading 600,000 units of TFFP stock currently worth $150,000.
tff pharmaceuticals, inc. is a clinical-stage biopharma company focused on developing and commercializing drug products based on its patented thin film freezing (tff) technology. our patented thin film freezing (tff) platform makes it possible to turn more molecules into inhalable therapies. this novel technology provides high absorption and yield, uniform particle size, gentle process and endless possibilities. tff pharmaceuticals has two lead drug candidates: voriconazole inhalation powder and tac-lac inhalation powder. the company plans to add to this pipeline by collaborating with large pharmaceutical partners. the tff platform is protected by 42 patents issued or pending in the us and internationally.
Tff Pharmaceuticals Inc executives and other stock owners filed with the SEC include: